Day Zero Diagnostics

Day Zero Diagnostics develops genome sequencing-based diagnostic solutions for infectious diseases, combining machine learning and whole-genome sequencing to rapidly identify infecting bacterial species and drug resistance profiles. The company's key assays include Blood2Bac, a culture-free bacterial enrichment technology, and BacDetect, which uses whole-genome sequencing to detect both species and antimicrobial resistance directly from clinical samples. This approach aims to reduce the time to actionable diagnostic results from days to hours, addressing the critical need for rapid diagnostics in sepsis and other severe bacterial infections. Founded in 2016 and headquartered in Boston, Massachusetts, Day Zero Diagnostics has raised approximately $49 million in Series B funding from investors including CARB-X, NIH, Becton Dickinson, Sands Capital Ventures, Triventures, and Panacea Venture.